Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations
Open Access
- 18 February 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (11) , 2673-2680
Abstract
Purpose: Prostate cancers with mutations in genes involved in homologous recombination (HR), most commonly BRCA2, respond favorably to PARP inhibition and platinum-based chemotherapy. We investigated whether other prostate tumors that do not harbor deleterious mutations in these particular genes can similarly be deficient in HR, likely rendering those sensitive to HR-directed therapies. Experimental Design: Homologous recombination deficiency (HRD) levels can be estimated using various mutational signatures derived from next-generation sequencing data. We used this approach on whole-genome sequencing (WGS; n = 311) and whole-exome sequencing (WES) data (n = 498) of both primary and metastatic prostate adenocarcinomas to determine whether prostate cancer cases display clear signs of HRD in somatic tumor biopsies. Results: Known BRCA-deficient samples showed all previously described HRD-associated mutational signatures in the WGS data. HRD-associated mutational signatures were also detected in a subset of patients who did not harbor germline or somatic mutations in BRCA1/2 or other HR-related genes. Similar results, albeit with lower sensitivity and accuracy, were also obtained from WES data. Conclusions: These findings may expand the number of cases likely to respond to PARP inhibitor treatment. On the basis of the HR-associated mutational signatures, 5% to 8% of localized prostate cancer cases may be good candidates for PARP-inhibitor treatment (including those with BRCA1/2 mutations).Keywords
All Related Versions
Funding Information
- Research and Technology Innovation (KTIA_NAP_13-2014-0021, NAP2-2017-1.2.1-NKP-0002)
- Breast Cancer Research Foundation (BCRF-17-156)
- Novo Nordisk Foundation Interdisciplinary Synergy Program (NNF15OC0016584)
- Det Fri Forskningsrad (W81XWH-18-2-0056)
- Danish Cancer Society ((R90-A6213;)
This publication has 41 references indexed in Scilit:
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repairNature, 2015
- Sequenza: allele-specific copy number and mutation profiles from tumor sequencing dataAnnals of Oncology, 2014
- Signatures of mutational processes in human cancerNature, 2013
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging AgentsCancer Discovery, 2012
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group TrialInternational Journal of Gynecological Cancer, 2010
- Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosisBritish Journal of Cancer, 2010
- A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancerGynecologic Oncology, 2006